Treats megaloblastic anemias due to folic acid deficiency. ANDA 207226, held by Fresenius Kabi USA. Leucovorin Calcium.
As of Nov 16, 2026, ANDA 207226 (Leucovorin Calcium), held by Fresenius Kabi USA, was first approved by FDA on Jul 27, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 27, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Leucovorin CalciumEQ 500MG BASE/50ML (EQ 10MG BASE/ML) · solution;intramuscular, intravenous | Leucovorin Calcium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters